{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:11:49Z","timestamp":1783350709369,"version":"3.54.6"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13555-024-01250-9","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T20:15:36Z","timestamp":1724444136000},"page":"2577-2589","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Teneralli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"issue":"1","key":"1250_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1529-8019.2008.00170.x","volume":"21","author":"J Hong","year":"2008","unstructured":"Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. Dermatol Ther. 2008;21(1):54\u20139.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/09546634.2018.1528330","volume":"30","author":"DJ Pithadia","year":"2019","unstructured":"Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management. J Dermatolog Treat. 2019;30(5):435\u201340.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/09546634.2019.1572865","volume":"31","author":"DJ Pithadia","year":"2020","unstructured":"Pithadia DJ, Reynolds KA, Lee EB, Wu JJ. Psoriasis-associated itch: etiology, assessment, impact, and management. J Dermatolog Treat. 2020;31(1):18\u201326.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1250_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2475530319854781","volume":"4","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Han C, Li S, et al. Correlation of physician-assessed psoriasis area and severity index score with patient-reported psoriais symptoms and signs diary scores among patients with moderate-to-severe psoriasis: results From VOYAGE\u00a01 and VOYAGE\u00a02 studies. J Psorias Psoriat Arthritis. 2019;4(3):147\u201352.","journal-title":"J Psorias Psoriat Arthritis"},{"issue":"4","key":"1250_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1468-3083.2000.00085.x","volume":"14","author":"H Devrimci-Ozguven","year":"2000","unstructured":"Devrimci-Ozguven H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14(4):267\u201371.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/jid.2014.530","volume":"135","author":"FJ Dalgard","year":"2015","unstructured":"Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984\u201391.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/jid.2013.508","volume":"134","author":"EA Dowlatshahi","year":"2014","unstructured":"Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 2014;134(6):1542\u201351.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1250_CR8","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1046\/j.1365-2133.2002.04742.x","volume":"146","author":"R Zachariae","year":"2002","unstructured":"Zachariae R, Zachariae H, Blomqvist K, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol. 2002;146(6):1006\u201316.","journal-title":"Br J Dermatol"},{"issue":"9","key":"1250_CR9","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"AB Kimball","year":"2010","unstructured":"Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24(9):989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1250_CR10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514\u201321.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00128071-200506060-00005","volume":"6","author":"AB Kimball","year":"2005","unstructured":"Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y. The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005;6(6):383\u201392.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1250_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","volume":"63","author":"RG Langley","year":"2010","unstructured":"Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase\u00a0III trial. J Am Acad Dermatol. 2010;63(3):457\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jdv.15012","volume":"32","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the phase\u00a03 VOYAGE\u00a02 study. J Eur Acad Dermatol Venereol. 2018;32(11):1940\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1250_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2340\/00015555-2833","volume":"98","author":"JH Hesselvig","year":"2018","unstructured":"Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335\u20139.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"1250_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.12106","volume":"28","author":"PL Mattei","year":"2014","unstructured":"Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1250_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000113150","volume":"216","author":"DA Revicki","year":"2008","unstructured":"Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008;216(3):260\u201370.","journal-title":"Dermatology"},{"issue":"6","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1189\/jlb.0212101","volume":"92","author":"MM Elloso","year":"2012","unstructured":"Elloso MM, Gomez-Angelats M, Fourie AM. Targeting the Th17 pathway in psoriasis. J Leukoc Biol. 2012;92(6):1187\u201397.","journal-title":"J Leukoc Biol"},{"issue":"10281","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"issue":"1","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.13712","volume":"1437","author":"ME Bauer","year":"2019","unstructured":"Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437(1):57\u201367.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1250_CR20","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","volume":"130","author":"L Capuron","year":"2011","unstructured":"Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226\u201338.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446\u201357.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"1250_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/PSY.0b013e3181907c1b","volume":"71","author":"MB Howren","year":"2009","unstructured":"Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171\u201386.","journal-title":"Psychosom Med"},{"issue":"3","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase\u00a0III, double-blinded, placebo- and active comparator-controlled VOYAGE\u00a01 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1250_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jaad.2009.07.022","volume":"62","author":"A Menter","year":"2010","unstructured":"Menter A, Augustin M, Signorovitch J, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010;62(5):812\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1250_CR25","unstructured":"Janssen Biotech. TREMFYA (guselkumab) injection, for subcutaneous use. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf. Accessed 1 Dec 2022."},{"issue":"3","key":"1250_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator-controlled VOYAGE\u00a02 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370.","journal-title":"Acta Psychiatr Scand"},{"issue":"3(Suppl)","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jaad.2022.06.642","volume":"87","author":"B Strober","year":"2022","unstructured":"Strober B, Liu Y-H, Yang Y-W, et al. Correlation of fatigue severity and psoriasis severity, and the treatment effect of guselkumab: a detailed analysis of SF-36 vitality scores from the VOYAGE\u00a02 study. J Am Acad Dermatol. 2022;87(3(Suppl)):153.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1250_CR30","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase\u00a03 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23(1):190.","journal-title":"Arthritis Res Ther"},{"key":"1250_CR31","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.2147\/NDT.S340388","volume":"17","author":"CH Liu","year":"2021","unstructured":"Liu CH, Hua N, Yang HY. Alterations in peripheral C-reactive protein and inflammatory cytokine levels in patients with panic disorder: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2021;17:3539\u201358.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"1250_CR32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/da.22084","volume":"30","author":"AH Miller","year":"2013","unstructured":"Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297\u2013306.","journal-title":"Depress Anxiety"},{"issue":"2","key":"1250_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1037\/a0031034","volume":"18","author":"L Valeri","year":"2013","unstructured":"Valeri L, VanderWeele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods. 2013;18(2):137\u201350.","journal-title":"Psychol Methods"},{"key":"1250_CR34","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1146\/annurev.psych.58.110405.085542","volume":"58","author":"DP MacKinnon","year":"2007","unstructured":"MacKinnon DP, Fairchild AJ, Fritz MS. Mediation analysis. Annu Rev Psychol. 2007;58:593\u2013614.","journal-title":"Annu Rev Psychol"},{"issue":"9","key":"1250_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.2340\/00015555-3181","volume":"99","author":"EL Simpson","year":"2019","unstructured":"Simpson EL, Yosipovitch G, Bushmakin AG, et al. Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: a mediation analysis. Acta Derm Venereol. 2019;99(9):756\u201361.","journal-title":"Acta Derm Venereol"},{"key":"1250_CR36","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.bodyim.2016.08.004","volume":"19","author":"P Lakuta","year":"2016","unstructured":"Lakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezinska-Wcislo L. The relationship between psoriasis and depression: a multiple mediation model. Body Image. 2016;19:126\u201332.","journal-title":"Body Image"},{"key":"1250_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.comppsych.2016.08.001","volume":"70","author":"M Innamorati","year":"2016","unstructured":"Innamorati M, Quinto RM, Imperatori C, et al. Health-related quality of life and its association with alexithymia and difficulties in emotion regulation in patients with psoriasis. Compr Psychiatry. 2016;70:200\u20138.","journal-title":"Compr Psychiatry"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01250-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:46:25Z","timestamp":1726145185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01250-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"1 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has served as a research investigator, scientific advisor, and\/or speaker for AbbVie, Almirall, Arcutis, ASLAN, Beiersdoft, BI, BMS, EPI, Incyte, LEO, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, and Pfizer. Peter Foley has received grant support and\/or travel grants and\/or honoraria from and\/or served as an investigator and\/or advisory board member and\/or consultant and\/or speaker for AbbVie, Akaal, Amgen, Arcutis, Argenx, Aslan, AstraZeneca, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene, Celtaxsys, CSL, CSL Seqirus, Cutanea, Dermira, Eli Lilly, Evelo Biosciences, Galderma, Genentech, GenesisCare, GlaxoSmithKline, Hexima, Incyte, Janssen, Kymab, LEO Pharma, Mayne Pharma, MedImmune, Melaseq\/Geneseq, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Reistone, Roche, Sanofi, Sun Pharma, Teva, UCB Pharma, and Valeant. Anthony Bewley has received ad hoc consultancy and\/or travel bursaries from Abbvie, Almirall, Galderma, Leo Pharma, Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB. Kenneth B. Gordon has received research\/grant support and\/or honoraria for consultation from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and UCB Pharma. Kim A. Papp has received clinical research grants and\/or honoraria as a consultant, and\/or speaker, and\/or investigator, and\/or scientific officer, and\/or advisory board member, and\/or Steering Committee member for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health\/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck-Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis\/Genzyme, Sun Pharma, Takeda and UCB. Rachel E. Teneralli, and Chenglong Han are employees of Janssen Global Services, LLC, Ya-Wen Yang is an employee of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, and Megan Miller is an employee of Janssen Research & Development, LLC; employees may own stock in Johnson & Johnson, of which Janssen is a subsidiary. Yan Liu was an employee of Janssen Global Services, LLC, at the time this study was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on data from previously conducted studies, VOYAGE\u00a01 (NCT02207231) and VOYAGE\u00a02 (NCT 02207244), which were conducted in accordance with the Declaration of Helsinki and were consistent with good clinical practices and regulatory requirements. Patients provided written informed consent prior to enrollment in either trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}